A clinical team has spearheaded the use of CAR-T cell therapy for blood cancers. The researchers recently treated the first ...

By drastically enhancing the effectiveness of CD19 CAR T-cell therapies against lymphoma cells with low or no CD19 antigen expression, Aleta is set to increase B-cell cancer cure rates significantly.

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

CAR-T cell therapy has revolutionized the treatment of relapsed and refractory B-acute lymphoblastic leukemia (B-ALL), with remission rates reaching as high as 90%. This therapy modifies a patient’s T ...

Frederick L. Locke, MD, discussed cema-cel's safety, efficacy, and potential for treating large B-cell lymphoma in earlier ...

Despite its promise, autologous chimeric antigen receptor T-cell (CAR T-cell) therapy faces several challenges, including limited accessibility, high costs and manufacturing bottlenecks. Allogeneic ...

CAR-T cell therapy involves extracting a patient's T-cells, modifying them to recognize cancer cells, and then reinfusing them into the patient where they target cancer cells throughout the body.

New CAR-T cell therapy shows promise for hard-to-treat cancers Date: March 10, 2025 Source: University of Colorado Anschutz Medical Campus Summary: Researchers have successfully developed a ...

The research team, led by Professors Kwong Yok-lam (front right) and Eric Tse Wai-choi (front left), successfully utilises ...